Top

Published in:

01-07-2006

The Prognostic Importance of Sentinel Lymph Node Biopsy in Thin Melanoma

Authors: Jaime M. Ranieri, MD, Jeffrey D. Wagner, MD, Stacie Wenck, RNP, Cynthia S. Johnson, MA, John J. Coleman III, MD

Published in: Annals of Surgical Oncology | Issue 7/2006

Abstract

Background

Sentinel lymph node biopsy (SLNB) is prognostically useful in patients with cutaneous melanoma with Breslow thickness >1 mm. The objective of this study was to determine whether sentinel node histology has similar prognostic importance in patients with thin melanomas (≤1 mm).

Methods

This was a retrospective study of patients who underwent SLNB for clinically localized melanoma at Indiana University Medical Center between 1994 and 2003. SLNB results and traditional melanoma prognostic indicators were studied in univariate log-rank tests.

Results

One hundred eighty-four patients with melanomas ≤1 mm thick underwent SLNB. SLNB was tumor positive in 12 patients (6.5%). Univariate analysis of SLNB results revealed that Breslow thickness, Clark level of invasion, and mitotic index were associated with SLNB status. Tumor positivity was observed at different rates in tumor thickness subsets: <.75 mm, 2.3%; and .75 to 1.0 mm, 10.2% (P = .0372). Disease-free survival and overall survival were significantly associated with SLNB results in melanomas ≤1 mm (log-rank test: P < .0001 and P = .0125, respectively) at a median follow-up of 26.3 months.

Conclusions

SLNB histology in melanomas ≤1.0 mm deep is a significant predictor of outcome. SLNB should be considered for selected patients with melanomas .75 to 1.0 mm.

Lipsker DM, Hedelin G, Heid E, et al. Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. Arch Dermatol 1999; 135:1451–6 PubMedCrossRef

Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635–48PubMed

Woods JE, Soule EH, Creagan ET. Metastasis and death in patients with thin melanomas (< 0.76 mm). Ann Surg 1983; 198:63–4PubMed

Mansson-Brahme E, Carstensen J, Erhardt K, et al. Prognostic factors in thin cutaneous malignant melanoma. Cancer 1994; 73:2324–32PubMed

Slingluff CL, Vollmer RT, Reintgen DS, et al. Lethal “thin” malignant melanoma: identifying patients at risk. Ann Surg 1988; 208:150–61PubMed

Naruns PL, Nizze JA, Cochran AJ, et al. Recurrence potential of thin primary melanomas. Cancer 1986; 57:545–8PubMed

Corsetti RL, Allen HM, Wanebo HJ. Thin ≤1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol 2000; 7:456–60PubMedCrossRef

Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 2002; 138:603–8PubMedCrossRef

Bedrosian I, Faries MB, Guerry D, et al. Incidence of sentinel node metastases in patients with thin primary melanoma (≤1 mm) with vertical growth phase. Ann Surg Oncol 2000; 7:262–7PubMedCrossRef

10.

Oliveira Filho RS, Ferreira LM, Biasi LJ, et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 2003; 36:347–50PubMedCrossRef

11.

Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000; 89:453–62PubMedCrossRef

12.

Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976–83PubMed

13.

Wagner JD, Ranieri J, Evdokimow DZ, et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg 2003; 112:486–97PubMedCrossRef

14.

Lowe JB, Hurst E, Moley JF, et al. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol 2003; 139:617–21PubMedCrossRef

15.

Muller MG, Leeuwen PA, vanDiest PJ, et al. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. Melanoma Res 2001; 11:303–7CrossRef

16.

Morton DL, Wen DR, Wong JH, et al. Technical details of intra-operative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392–9PubMed

17.

Jacobs IA, Chang CK, DasGupta TK, et al. Role of sentinel lymph node biopsy in patients with thin (< 1 mm) primary melanoma. Ann Surg Oncol 2003; 10:558–61PubMedCrossRef

18.

Nahabedian MY, Tufaro AP, Manson PN. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary? Ann Plast Surg 2003; 50:601–6PubMedCrossRef

19.

Schmid-Wendtner MH, Baumert J, Schmidt M, et al. Prognostic index for cutaneous melanoma: an analysis after follow-up of 2715 patients. Melanoma Res 2001; 11:619–26PubMedCrossRef

20.

Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic index is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97:1488–98PubMedCrossRef

21.

Kesmodel SB, Karakousis GC, Botbyl JP, et al. Mitotic rate as a predictor for sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005; 12:449–58PubMedCrossRef

22.

Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622–34PubMed

23.

Finley JW, Gibbs JF, Rodriguez LM, et al. Pathologic and clinical features influencing outcome of thin melanoma: correlation with newly proposed staging system. Am Surg 2000; 66:527–31PubMed

24.

Agnese DM, Abdessalam SF, Burak WE, et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003; 134:542–7PubMedCrossRef

Title: The Prognostic Importance of Sentinel Lymph Node Biopsy in Thin Melanoma
Authors: Jaime M. Ranieri, MD
Jeffrey D. Wagner, MD
Stacie Wenck, RNP
Cynthia S. Johnson, MA
John J. Coleman III, MD
Publication date: 01-07-2006
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 7/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/ASO.2006.04.023

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Prognostic Importance of Sentinel Lymph Node Biopsy in Thin Melanoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2006

Initial Outcomes for Patients Treated on the American Society of Breast Surgeons MammoSite Clinical Trial for Ductal Carcinoma-In-Situ of the Breast

Three–Axillary Lymph Node Sampling for the Prediction of Nonsentinel Node Metastases in Breast Cancer Patients With Sentinel Node Metastases

Prognostic Significance of Molecular Staging Study of Sentinel Lymph Nodes by Reverse Transcriptase-Polymerase Chain Reaction for Tyrosinase in Melanoma Patients

Local Recurrences After Conservative Treatment of Ductal Carcinoma-In-Situ of the Breast Without Radiotherapy: The Effect of Age

High Serum Concentrations of Sialyl Lewisx Predict Multilevel N2 Disease in Non–Small-Cell Lung Cancer

Specific Gene-Expression Profiles of Noncancerous Liver Tissue Predict the Risk for Multicentric Occurrence of Hepatocellular Carcinoma in Hepatitis C Virus–Positive Patients